Characteristics of Industry-Sponsored Drug Clinical Trials Registered in Japan Pharmaceutical Information Center Clinica
- PDF / 809,377 Bytes
- 10 Pages / 595.276 x 790.866 pts Page_size
- 14 Downloads / 234 Views
ORIGINAL RESEARCH
Characteristics of Industry‑Sponsored Drug Clinical Trials Registered in Japan Pharmaceutical Information Center Clinical Trials Information 2010–2018 Eriko Kobayashi1 · Midori Matsuyama2 · Katsue Suzuki2 · Takahisa Murakami2 · Mamoru Narukawa3 Received: 21 May 2020 / Accepted: 19 September 2020 © The Drug Information Association, Inc 2020
Abstract Purpose To examine the trends and characteristics of industry-sponsored drug clinical trials registered in the JapicCTI (Japan Pharmaceutical Information Center Clinical Trials Information) in 2010–2018. Methods A data set of 3116 clinical trials registered from Jan. 2010 to Dec. 2018 were analyzed. Fundamental characteristics of the clinical trials were analyzed by 3-year time periods. The analysis was also focused on 3 therapeutic areas: cardiovascular, mental health, and oncology. Results Of all the trials (2010–2018), 74.7% were conducted in Japan only; the rate decreased from 82.8 to 65.3% over the 3 time periods. Most trials were phase 3 trials, which comprised 44.1% of the trials. Small trials (anticipated number of 1000 or fewer participants) made up 94.0% of the trials. Oncology trials (29.5%) were the most common type and involved more phase 1 trials than mental health and cardiovascular trials (33.6% vs 14.5% and 11.5%, respectively). Oncology trials composed the smallest proportion of trials conducted in “Japan only” at 57.3% vs 81.0% and 83.1% for mental health and cardiovascular trials, respectively (p
Data Loading...
